You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

Article info

Article menu

Download PDFPDF

XML
Meta analysis
Hepatology
Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

Authors

  • Bin Wei Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Fanpu Ji Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USADepartment of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaShaanxi Provincial Clinical Research Center for Hepatic & Splenic Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China PubMed articlesGoogle scholar articles
  • Yee Hui Yeo Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Eiichi Ogawa Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USADepartment of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan PubMed articlesGoogle scholar articles
  • Biyao Zou Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Christopher D Stave Lane Medical Library, Stanford University School of Medicine, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Shuangsuo Dang Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China PubMed articlesGoogle scholar articles
  • Zongfang Li Shaanxi Provincial Clinical Research Center for Hepatic & Splenic Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaNational & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China PubMed articlesGoogle scholar articles
  • Norihiro Furusyo Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan PubMed articlesGoogle scholar articles
  • Ramsey C Cheung Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USADivision of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Mindie H Nguyen Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mindie H Nguyen; mindiehn{at}stanford.edu
View Full Text

Citation

Wei B, Ji F, Yeo YH, et al
Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis
BMJ Open Gastroenterology 2018;5:e000207. doi: 10.1136/bmjgast-2018-000207

Publication history

  • Received March 15, 2018
  • Revised June 2, 2018
  • Accepted June 8, 2018
  • First published June 29, 2018.
Online issue publication 
April 30, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/